Goodson Jason Daniel's Form 4 filing
Keenova Therapeutics plcMNKTQ · filed Mar 17, 2023
- Accession no.
- 0001104659-23-033845
- Filed
- Mar 17, 2023
- Trade date
- Mar 16, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $9.50K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goodson Jason DanielCIK 0001944331 | Officer (EVP & Head of Corp Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | Ordinary Shares | PPurchaseAcquired | +200 | $8.35 | +$1,670 | 37,745 | Direct | |
| Mar 16, 2023 | Ordinary Shares | PPurchaseAcquired | +933 | $8.39 | +$7,827.87 | 38,678 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014